Semaglutide Drug Interactions to Know

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Most Ozempic side effects are short-term, improving after about 3 months as your body adjusts to the medication.
Long-term issues can include pancreatitis, vision problems, kidney injury, and skin changes such as 'Ozempic face' or 'Ozempic body'.
In a 2-year study, 3% of Ozempic injection users experienced diabetic retinopathy complications, compared to 1.8% taking a placebo.
Semaglutide has been linked to potential thyroid tumors in rodent studies, but it is not known if this applies to humans.

Semaglutide, known by brand names like Ozempic and Wegovy, is a medication widely used for type 2 diabetes and increasingly for weight loss. While many people experience its benefits, understanding its potential long-term side effects is crucial. Most side effects are temporary, often resolving within a few months as the body adapts to the medication. However, some complications can persist, including pancreatitis, vision problems, and kidney injury, which may last for months or even years after stopping the drug. For instance, in one 2-year study, 8 people taking injectable Ozempic experienced pancreatitis, compared to 10 people taking a placebo, highlighting the need for careful monitoring. Additionally, a serious concern involves potential thyroid tumors, observed in rodent studies with semaglutide and similar drugs, though it is not yet known if this risk extends to humans.

What Are the Common Side Effects of Semaglutide?

Semaglutide medications like Ozempic and Wegovy are associated with a range of side effects, most of which are mild to moderate and generally improve over time. These common issues often appear when a person first starts taking the medication or after a dose increase. Understanding these initial reactions can help manage expectations and ensure continued adherence to treatment under medical guidance.

The most frequently reported side effects include gastrointestinal discomforts. Users may experience abdominal pain or general discomfort in the stomach area. Loss of appetite is also common, which for many using semaglutide for weight loss, is a desired effect, but it can sometimes lead to issues if not managed properly. Indigestion or heartburn are other typical complaints. Furthermore, some individuals report reactions at the injection site, such as redness, swelling, or itching, where the medication is administered. These symptoms are usually temporary and tend to subside as the body gets used to the drug. For most people, these initial Ozempic side effects improve after about 3 months, indicating a period of adjustment for the body.

It is important to differentiate these common, often transient, side effects from the more serious, albeit rarer, long-term complications. While unpleasant, these common issues rarely pose a significant health risk if managed appropriately. Healthcare providers often recommend starting semaglutide at a low dose and gradually increasing it. This gradual titration helps the body adjust, which can reduce the likelihood that side effects, especially nausea and other GI symptoms, disrupt treatment. This approach is specifically designed to minimize the impact of these initial reactions, allowing individuals to continue their medication regimen more comfortably. The goal is to allow the body to slowly adapt to the medication, making the treatment more tolerable in the long run.

Monitoring these common side effects is part of routine care when starting semaglutide. Patients are encouraged to communicate any persistent or worsening symptoms to their healthcare provider. Simple dietary adjustments, timing of medication, or over-the-counter remedies might help alleviate some of these common complaints. For example, eating smaller, more frequent meals, avoiding fatty or spicy foods, and staying hydrated can often lessen gastrointestinal distress. Injection site reactions are usually mild and can be managed with local care. The key is to recognize that these are often part of the body's initial adjustment to the medication and are not necessarily indicators of a severe underlying problem.

Managing Common Gastrointestinal Issues

Gastrointestinal issues are among the most commonly reported side effects of Ozempic, impacting many users. These can include nausea, vomiting, diarrhea, or abdominal pain. While often mild, these symptoms can sometimes be severe enough to cause concern, and if not managed well, they could potentially lead to dehydration or even malnutrition. This emphasizes the importance of close monitoring and communication with a healthcare provider, especially when first starting the medication or increasing the dose.

The mechanism behind these gastrointestinal effects is related to how semaglutide works. It slows down gastric emptying, meaning food stays in the stomach for a longer period. This can contribute to feelings of fullness, which is beneficial for weight loss, but it can also lead to discomfort, bloating, and nausea. When the stomach empties more slowly, there's a higher chance of food remaining in the stomach, which can trigger symptoms like indigestion or a feeling of being overly full even after small meals.

Strategies to manage these issues often involve dietary modifications. Eating smaller, more frequent meals instead of large ones can help reduce the burden on the digestive system. Avoiding high-fat foods, which take longer to digest, can also be beneficial. Staying well-hydrated is critical, especially if experiencing diarrhea or vomiting, to prevent dehydration. Over-the-counter anti-nausea medications or antacids might be recommended by a healthcare provider for temporary relief. The goal is to make the adjustment phase as comfortable as possible, allowing individuals to continue benefiting from the medication.

These symptoms are most likely to occur when first starting Ozempic or after a dose increase. They are generally temporary and may subside as your body adjusts to the medication. For most people, this means Ozempic side effects after 3 months improve. This timeframe highlights a critical period during which patients and providers need to work closely to optimize treatment and manage any discomfort. The body's ability to adapt to the medication's effects is a key factor in the long-term success and tolerability of semaglutide therapy.

Can Semaglutide Cause Long-Term Health Problems?

Yes, semaglutide has been associated with certain long-term side effects that may persist for months or even years after discontinuing the medication. While many users experience only temporary side effects that resolve as their body adjusts, it is important to be aware of the potential for more enduring health issues. These long-term problems, though often rare, warrant careful consideration and discussion with a healthcare provider before starting treatment.

Examples of long-term side effects that individuals may experience from Ozempic include pancreatitis, vision problems, kidney injury, and changes in skin appearance, sometimes referred to as 'Ozempic face'. The possibility of these lasting effects underscores the need for comprehensive patient education and ongoing medical supervision throughout the course of treatment. Clinical trials have provided valuable data on the duration and scope of these potential long-term issues. Ozempic was studied for 30 weeks for type 2 diabetes, and for 104 weeks in studies focused on cardiovascular outcomes, known as the SUSTAIN trials. Another significant trial extended for 41 months, observing adults with type 2 diabetes and chronic kidney disease. These extensive study periods help clinicians understand the potential for effects that may not manifest in shorter trials.

The duration of these studies is crucial because some health issues take time to develop or become apparent. For instance, chronic conditions like kidney injury or the progression of eye diseases might not be evident in short-term observations. The data gathered over these extended periods allows for a more complete picture of semaglutide's safety profile beyond its immediate effects. Patients should be aware that while the medication is highly effective for blood sugar control and weight management, it carries these potential long-term considerations.

It is important to review the full product information for semaglutide and discuss individual risks with a healthcare provider. The occurrence of these long-term effects is not universal, and many people use semaglutide without experiencing them. However, being informed about these possibilities allows for proactive monitoring and early intervention if any symptoms arise. The balance between the benefits of semaglutide in managing diabetes and weight, and the potential for these long-term complications, is a key aspect of personalized medical decision-making.

Understanding Persistent Side Effects

While many side effects are temporary, some complications linked to semaglutide can persist over extended periods. This persistence can be a significant concern for individuals undergoing treatment. For example, issues such as pancreatitis, vision problems, and kidney injury, once they develop, may require ongoing management even after the medication is stopped. This highlights the complex nature of drug interactions within the body and the potential for lasting impacts on various organ systems.

The concept of "Ozempic face" or "Ozempic body" refers to changes in body composition that can occur with rapid weight loss. While not a direct side effect of the drug's chemical action, it is a consequence of the rapid fat loss that semaglutide can induce. This can lead to a gaunt appearance in the face or sagging skin elsewhere on the body due to the loss of subcutaneous fat. These aesthetic changes, while not medically harmful, can be distressing for some individuals and may require cosmetic interventions if they persist. The rapid nature of weight reduction, rather than the drug itself, is the primary driver of these specific body composition changes.

Kidney Health and Semaglutide

Kidney injury and function loss are listed among the potential long-term Ozempic issues. While Ozempic may help protect heart and kidney health in people with type 2 diabetes or obesity, there are also reports of kidney issues. This duality means that while the drug can offer protective benefits for some patients, particularly those with pre-existing conditions that put their kidneys at risk, it also carries a rare risk of adverse effects on kidney function in others. Close monitoring of kidney function, especially in patients with pre-existing kidney disease, is crucial.

The long-term studies, including one lasting 41 months in adults with type 2 diabetes and chronic kidney disease, provide a basis for understanding these effects. These studies are designed to capture changes in organ function over extended periods, offering insights into both beneficial and adverse outcomes. Patients with any history of kidney problems should have a detailed discussion with their doctor about the risks and benefits of semaglutide. Regular kidney function tests are an important part of monitoring during treatment to detect any changes early.

Is Pancreatitis a Risk with Semaglutide?

Pancreatitis, which is an inflammation of the pancreas, has been reported in some individuals who took Ozempic during clinical trials. This condition can be serious, involving severe abdominal pain and digestive issues, and in some cases, it can be life-threatening. Despite these reports, it remains unclear if Ozempic directly causes pancreatitis. The relationship between semaglutide and pancreatitis is complex, with ongoing research and differing findings across studies.

For example, in one 2-year study, 8 people taking injectable Ozempic experienced pancreatitis, compared to 10 people taking a placebo, which contained no active medication. This particular finding suggests that the incidence was actually slightly lower in the Ozempic group than in the placebo group in this specific study, making it difficult to definitively link the drug to an increased risk. In pooled studies involving oral semaglutide, available as Rybelsus or an Ozempic tablet, 6 people reported pancreatitis compared to 1 in the comparator group. This data from oral semaglutide trials shows a higher incidence in the treatment group, suggesting a potential association.

However, a more recent meta-analysis, which combined data from about 35,000 patients, found that semaglutide is not associated with a higher risk of pancreatitis when compared to a placebo. This large-scale analysis provides a broader perspective, suggesting that the overall risk might not be significantly elevated. Despite these conflicting findings, cases of people taking the medication continue to report pancreatitis, meaning vigilance is still necessary. The medical community continues to monitor these reports closely to better understand any causal links.

Patients using semaglutide need to be aware of the signs and symptoms of pancreatitis. These may include severe upper stomach pain that can radiate to the back, often accompanied by nausea or vomiting, and a rapid heartbeat. Pancreatitis usually resolves within 2 weeks, but it can sometimes last longer. There was one report of chronic, or long-term, pancreatitis in a single patient taking Ozempic during clinical trials, indicating that in very rare instances, the condition can become prolonged.

Understanding Pancreatitis Symptoms

Recognizing the symptoms of pancreatitis early is critical for prompt medical attention. The most prominent symptom is severe upper stomach pain. This pain is often described as sharp or burning and can radiate to the back, distinguishing it from other types of abdominal discomfort. The intensity of the pain can be quite debilitating, affecting daily activities.

Along with pain, patients often experience nausea and vomiting. These digestive issues can be severe and contribute to dehydration. A rapid heartbeat is another symptom that may occur, as the body reacts to the inflammation and pain. Other signs can include fever, tenderness in the abdomen, and sometimes jaundice (yellowing of the skin or eyes) if the bile duct is also affected.

If you experience any of these symptoms while taking semaglutide, it is important to seek immediate medical help. Early diagnosis and treatment are crucial to manage pancreatitis effectively and prevent potential complications. While pancreatitis usually resolves within a couple of weeks, the rare possibility of it becoming chronic means that any suspicious symptoms should not be ignored.

Gallbladder Disease as a Concern

Gallbladder disease and complications are also listed among the rare but serious long-term Ozempic side effects. The gallbladder is a small organ that stores bile, which helps in digesting fats. When it becomes inflamed or develops stones, it can lead to significant pain and other digestive issues. This condition is known as cholecystitis (inflammation) or cholelithiasis (gallstones).

The exact mechanism linking semaglutide to gallbladder problems is not fully understood, but rapid weight loss itself is a known risk factor for developing gallstones. Since semaglutide often leads to significant and sometimes rapid weight loss, it might indirectly increase the risk of gallbladder issues. This is an important consideration for individuals using semaglutide for weight management.

Symptoms of gallbladder problems can include sudden and intensifying pain in the upper right part of the abdomen, pain that radiates to the right shoulder or back, nausea, vomiting, and fever. If these symptoms occur, medical evaluation is necessary. Managing gallbladder issues might involve dietary changes, medication, or in some cases, surgical removal of the gallbladder.

How Does Semaglutide Affect Vision?

Semaglutide may impact vision, particularly by potentially worsening an existing eye condition known as diabetic retinopathy. This can occur, especially when blood sugar levels improve rapidly. Diabetic retinopathy is a complication of diabetes that affects the eyes, damaging the blood vessels in the light-sensitive tissue at the back of the eye (retina). While controlling blood sugar is generally beneficial for managing diabetes complications, a very rapid improvement can sometimes cause a temporary worsening of retinopathy, a phenomenon observed with intense glucose-lowering therapies.

In a 2-year study, 3% of Ozempic injection users experienced complications related to diabetic retinopathy, compared to 1.8% of those taking a placebo. This difference suggests a potential increase in risk for this specific complication among Ozempic users. Similarly, in pooled placebo and active-controlled trials, 4.2% of oral semaglutide users reported diabetic retinopathy compared to 3.8% in the comparator group. These statistics, while seemingly small, indicate a measurable effect that patients and healthcare providers should be aware of.

Another potential eye condition linked to Ozempic is non-arteritic anterior ischemic optic neuropathy (NAION). This condition occurs when the optic nerve, which transmits visual information from the eye to the brain, does not receive enough blood supply. NAION can lead to sudden, painless vision loss in one eye. While rare, it is a serious condition that can have lasting effects on vision. The exact link between semaglutide and NAION is not fully established, but it is listed as a potential concern.

Overall, vision problems and eye damage are listed as potential long-term issues associated with semaglutide. Given these potential risks, individuals with diabetes, especially those with pre-existing diabetic retinopathy, should have regular eye examinations while on semaglutide therapy. Close monitoring by an ophthalmologist can help detect any changes early and manage them appropriately. The benefits of semaglutide in managing blood sugar and weight must be weighed against these potential ocular risks, particularly for vulnerable patient populations.

Diabetic Retinopathy Worsening

The rapid improvement in blood sugar levels that semaglutide can achieve, while generally positive for diabetes management, can paradoxically lead to a temporary worsening of diabetic retinopathy. This phenomenon is known as early worsening of diabetic retinopathy or rapid glycemic control-induced retinopathy. It is thought to occur because the retinal blood vessels, which have adapted to high blood sugar levels, can be stressed by a sudden return to normal glucose levels, leading to increased leakage or bleeding.

For patients with pre-existing diabetic retinopathy, this means that while their overall diabetes control is improving, they might experience a temporary setback in their eye health. Symptoms of worsening retinopathy can include blurred vision, new floaters, or even vision loss. Regular dilated eye exams are crucial for these patients. An ophthalmologist can monitor the progression of retinopathy and advise on appropriate management strategies, which might include laser treatment or injections to preserve vision.

The statistics from clinical trials underscore this concern. The 3% of Ozempic injection users experiencing complications versus 1.8% on placebo in a 2-year study, and 4.2% of oral semaglutide users versus 3.8% in the comparator group, highlight a slight but significant increase in the incidence of diabetic retinopathy issues. This emphasizes the need for a collaborative approach between the endocrinologist managing the diabetes and the ophthalmologist monitoring eye health.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NAION is a condition where the optic nerve, vital for vision, experiences insufficient blood flow. This lack of blood supply can cause damage to the nerve, leading to sudden, often painless, vision loss. The vision loss typically occurs in one eye and can range from mild to severe. While it is a rare condition, its potential link to semaglutide is a serious concern.

The exact cause of NAION is often unclear, but it is associated with certain risk factors such as diabetes, high blood pressure, high cholesterol, sleep apnea, and certain medications. If semaglutide contributes to NAION, it would likely be through its effects on blood vessels or blood flow, although more research is needed to establish a definitive causal link.

Patients experiencing sudden vision loss or changes while on semaglutide should seek immediate medical attention from an eye specialist. Early diagnosis can sometimes help in managing the condition, although there is no definitive cure for NAION. This potential long-term effect adds another layer of complexity to the risk-benefit assessment of semaglutide therapy, particularly for individuals with pre-existing vascular risk factors.

What Are Other Serious Long-Term Side Effects?

Beyond pancreatitis and vision issues, semaglutide medications like Ozempic and Wegovy carry other rare but serious long-term side effects that demand attention. These include gallbladder problems, kidney issues, and a risk of thyroid tumors. These potential complications, though not common, highlight the importance of thorough patient evaluation and ongoing monitoring by healthcare professionals.

Ozempic can also cause gastrointestinal complications that are more severe than typical nausea or diarrhea. These include gastroparesis, often referred to as "stomach paralysis," and intestinal blockage. Gastroparesis slows or stops the movement of food from the stomach to the small intestine, leading to symptoms like severe nausea, vomiting, bloating, and early satiety. While these complications are rare, they can be serious and require medical intervention.

Rapid weight loss, a common and desired effect of semaglutide, can also lead to changes in body composition that manifest as "Ozempic face" or "Ozempic body." These terms describe the loss of fat, particularly in the face, which can lead to a gaunt appearance, or generalized sagging skin due to significant fat reduction. While not a direct medical side effect of the drug's mechanism, it is a consequence of the rapid body changes it induces.

A particularly significant warning associated with semaglutide medications is the risk of thyroid tumors. Wegovy, another semaglutide medication, explicitly states important safety information regarding possible thyroid tumors, including cancer. Patients are advised to tell their healthcare provider if they notice a lump or swelling in their neck, hoarseness, trouble swallowing, or shortness of breath, as these could be symptoms of thyroid cancer. Studies with rodents showed that Wegovy and other medicines that work similarly caused thyroid tumors, including thyroid cancer. However, it is not currently known if Wegovy will cause thyroid tumors or a specific type of thyroid cancer called medullary thyroid carcinoma (MTC) in humans. This distinction is crucial, as rodent studies do not always translate directly to human risk.

Thyroid Tumor Risk

The potential for thyroid tumors, including cancer, is one of the most serious long-term warnings for semaglutide medications. This concern stems from animal studies where Wegovy and similar drugs caused thyroid tumors in rodents. While the relevance of these findings to humans is not yet definitively established, the risk is significant enough to warrant a prominent warning.

Medullary thyroid carcinoma (MTC) is a rare but aggressive form of thyroid cancer. The safety information for Wegovy specifically mentions MTC and advises against using the medication if there is a personal or family history of this type of cancer, or if an individual has Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), which is a genetic condition predisposing to MTC. This strong contraindication highlights the seriousness with which this potential risk is viewed by regulatory bodies and manufacturers.

For individuals taking semaglutide, being vigilant for symptoms of thyroid issues is important. A lump or swelling in the neck, persistent hoarseness, difficulty swallowing, or shortness of breath are all potential signs that should be immediately reported to a healthcare provider. Regular check-ups and open communication with medical professionals are essential to monitor for any such developments during the course of treatment.

Gastroparesis and Intestinal Blockage

Gastroparesis, or "stomach paralysis," is a condition where the stomach muscles work poorly or not at all, preventing food from emptying properly. This can lead to chronic and severe gastrointestinal symptoms. Semaglutide, by design, slows gastric emptying to help with blood sugar control and satiety for weight loss. However, in some rare cases, this effect can be excessive, leading to gastroparesis-like symptoms or even a true gastroparesis.

Symptoms can include persistent nausea, vomiting of undigested food, feeling full after only a few bites, abdominal bloating, and pain. These symptoms can be debilitating and impact nutritional intake. Similarly, intestinal blockage, another rare but serious complication, involves a partial or complete obstruction of the intestines. This can cause severe abdominal pain, bloating, constipation, and vomiting.

Both gastroparesis and intestinal blockage are medical emergencies that require prompt diagnosis and treatment. Patients experiencing severe and persistent gastrointestinal symptoms should seek urgent medical attention. While these are rare occurrences, their severity necessitates awareness and rapid response from both patients and healthcare providers. According to Potential complications of Ozempic, gastrointestinal discomfort is one of the most commonly reported side effects of Ozempic.

Who Should Not Use Semaglutide?

Certain individuals should not use semaglutide medications like Ozempic and Wegovy due to significant health risks. These contraindications are critical for patient safety and are clearly outlined in the medication's safety information. Adhering to these guidelines is paramount to prevent serious and potentially life-threatening complications.

The most important information regarding Wegovy states that it may cause serious side effects, including possible thyroid tumors, specifically medullary thyroid carcinoma (MTC). Therefore, individuals with a personal history of MTC or a family history of MTC should not use Wegovy. This strict warning is in place because the medication's mechanism of action, as observed in animal studies, has shown a link to thyroid tumor development. While it's not known if this risk translates to humans, the potential severity of MTC necessitates this precaution.

Additionally, people with an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should also avoid using Wegovy. MEN 2 is a rare genetic disorder that increases the risk of developing tumors in several endocrine glands, including the thyroid gland (MTC), adrenal glands, and parathyroid glands. Because of the inherent increased risk of MTC in individuals with MEN 2, adding a medication that potentially stimulates thyroid tumor growth would be highly dangerous. This is a critical safety consideration that healthcare providers must thoroughly screen for before prescribing semaglutide. According to Wegovy important safety information, patients should tell their healthcare provider if they get a lump or swelling in their neck, hoarseness, trouble swallowing, or shortness of breath, as these may be symptoms of thyroid cancer.

The decision to prescribe semaglutide should always involve a comprehensive review of a patient's medical history, including family history of certain cancers and endocrine disorders. The potential benefits of blood sugar control and weight loss must be carefully weighed against these serious risks for each individual. For those with these specific contraindications, alternative treatments for diabetes or weight management should be explored.

Contraindications for Thyroid Cancer Risk

The most significant contraindication for semaglutide use relates to the risk of thyroid cancer. Specifically, if you or any of your family members have ever had medullary thyroid carcinoma (MTC), you should not use Wegovy. MTC is a rare but aggressive form of thyroid cancer, and the warning is based on animal studies showing a link between semaglutide and thyroid tumors. This is a crucial safety measure to prevent potentially fatal outcomes.

Similarly, individuals diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) are also advised against using semaglutide. MEN 2 is a genetic condition that significantly increases the risk of developing MTC, along with tumors in other endocrine glands. Because these individuals are already at a heightened risk for MTC, introducing a medication that could further promote its development is contraindicated. This is a non-negotiable safety guideline that healthcare providers must adhere to.

These contraindications highlight the importance of a detailed medical history before starting semaglutide. Patients should openly discuss any personal or family history of thyroid cancers or endocrine syndromes with their doctor. This information is vital for the healthcare provider to make an informed decision about the appropriateness and safety of semaglutide therapy. The safety information regarding Wegovy is clear on these points, aiming to protect patients from severe, rare complications. According to Ozempic long-term side effects, Ozempic has the potential to cause certain long-term problems that may last months or years after stopping it, including pancreatitis, vision problems, kidney injury, and skin changes.

Other Important Safety Considerations

Beyond the thyroid-related contraindications, there are other important safety considerations for semaglutide. While not absolute contraindications, certain conditions require careful monitoring and discussion with a healthcare provider. For instance, individuals with a history of pancreatitis should discuss this thoroughly with their doctor, even though a meta-analysis of 35,000 patients found no higher risk of pancreatitis with semaglutide compared to placebo.

Patients with diabetic retinopathy should also proceed with caution and ensure regular eye exams, as semaglutide may worsen this condition, especially with rapid blood sugar improvement. In a 2-year study, 3% of Ozempic injection users experienced complications versus 1.8% taking a placebo. This means that while the drug can offer benefits for overall diabetes management, it requires specific monitoring for ocular health.

Individuals with severe gastrointestinal disease, such as gastroparesis or inflammatory bowel disease, might also need careful evaluation due to semaglutide's effects on gastric emptying. The medication's mechanism of slowing digestion could exacerbate existing conditions or lead to new severe issues in susceptible individuals. The overall health profile and any pre-existing conditions must be thoroughly assessed to ensure the safe and effective use of semaglutide.

Frequently Asked Questions

What is 'Ozempic face'?

'Ozempic face' is a term used to describe changes in body composition that can occur with rapid weight loss induced by semaglutide. It refers to the loss of fat, particularly in the face, which can lead to a gaunt, hollowed-out appearance. This is not a direct side effect of the drug's chemical action but rather a consequence of significant and sometimes quick fat reduction throughout the body. While not a medical complication, these aesthetic changes can be distressing for some individuals.

Can Ozempic cause kidney damage?

Yes, kidney damage and function loss are listed as potential long-term Ozempic side effects. While Ozempic may help protect heart and kidney health in people with type 2 diabetes or obesity, there have been reports of kidney issues. Clinical trials, including one lasting 41 months in adults with type 2 diabetes and chronic kidney disease, help to understand these effects over time. Close monitoring of kidney function is important, especially for patients with pre-existing kidney conditions.

Are gastrointestinal issues common with Ozempic?

Yes, gastrointestinal issues are among the most commonly reported side effects of Ozempic. These can include nausea, vomiting, diarrhea, or abdominal pain. These symptoms are most likely to occur when first starting the medication or after a dose increase. For most people, these common side effects tend to improve after about 3 months as their body adjusts to the medication.

What are the signs of pancreatitis?

Pancreatitis is an inflammation of the pancreas, and while rare with Ozempic, it has been reported. Signs and symptoms of pancreatitis may include severe upper stomach pain that can radiate to the back, nausea or vomiting, and a rapid heartbeat. In one 2-year study, 8 people taking injectable Ozempic experienced pancreatitis compared to 10 people taking a placebo. If you experience these symptoms, it is important to seek medical attention immediately.

Is there a risk of thyroid cancer with semaglutide?

Yes, there is a warning about a risk of thyroid tumors, including cancer, with semaglutide medications like Wegovy. Studies with rodents showed that Wegovy and similar medicines caused thyroid tumors, including thyroid cancer. It is not known if Wegovy will cause thyroid tumors or medullary thyroid carcinoma (MTC) in people. Due to this potential risk, individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use Wegovy.

— The The GLP-1 Daily Team